Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc.

SRPTNYSE / NASDAQHealthcareMid cap

$13.33-$0.84 (-5.9%)

Last close · Data as of Nov 20, 2026

Market cap
$1.8B
P/E
-2.5x
EV / EBITDA
-3.2x
Revenue
$2.2B
Net margin
-32.5%
ROCE
-29.2%

-19.1% over the last year

Sarepta Therapeutics, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-30.5%
3M
-30.6%
6M
-22.1%
1Y
-19.1%
5Y
-83.3%

52-week range

Day change -$0.84 (-5.9%) from $14 to $13 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in SRPT, bought on each weekday since 2021.

News & filings

What Sarepta Therapeutics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 713 million US dollars in fiscal 2025.

Strengths (1)

  • Cash on the balance sheet equals 46% of the company's market value.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases.

Read moreShow less

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Sector
Healthcare
Shares outstanding
105.0M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.8B
P/E
-2.5x
P/B
1.5x
EV / EBITDA
-3.2x
EV / Sales
0.9x
P/S
0.8x
52-week high
$23.83
52-week low
$13.33

Profitability

Operating margin
-29.9%
Net margin
-32.5%
EBITDA margin
-28.2%
ROE
-62.5%
ROCE
-29.2%
ROA
-21.3%
Asset turnover
0.66

Growth

Revenue
$2.2B
Revenue growth, 1Y
15.6%
Revenue CAGR, 3Y
33.1%
Net profit growth, 1Y
-403.3%
Free cash flow
-$315.3M

Solvency

Current ratio
2.32
Debt / Equity
0.91
Debt / Assets
0.31
CFO / Net profit
0.29
Cash / Market cap
45.6%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$2.2B
Cost of revenue$839.6M
Gross profit$1.4B
Operating expenses$2.0B
Research and development$1.5B
Selling, general and administrative$491.7M
Operating income-$657.8M
Interest and other-$44.5M
Pretax income-$702.2M
Tax and other$11.2M
Net income-$713.4M

Revenue and net profit

Revenue grew 15.6% in FY2025; net profit is the dashed line.

Sarepta Therapeutics, Inc. revenue and net profit by fiscal year
Sarepta Therapeutics, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$933.0M-$703.5M
FY2023$1.2B-$536.0M
FY2024$1.9B$235.2M
FY2025$2.2B-$713.4M

Cash flows

FY2025: -$205.5M from operations, -$315.3M free after investment (dashed).

Sarepta Therapeutics, Inc. operating and free cash flow by fiscal year
Sarepta Therapeutics, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$325.3M-$357.6M
FY2023-$501.0M-$588.3M
FY2024-$205.8M-$352.7M
FY2025-$205.5M-$315.3M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$2.2B+15.6%1Y
EBITDA
-$619.6M-295.5%1Y
Net profit
-$713.4M-403.3%1Y
Cash from operations
-$205.5M
Free cash flow
-$315.3M
Revenue CAGR, 3Y
33.1%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$2.2B-$619.6M-$713.4M-$315.3M-62.5%+15.6%-403.3%

Monthly returns

Month-by-month returns of SRPT across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$3.3B
Liabilities$2.2B
Equity$1.1B
Paid-in capital$6.0B
Retained earnings-$4.9B
Treasury stock$25.3M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; SRPT highlighted.

P/E against peers

SRPT has no positive P/E; the peer median is 12.8x.

Not shown (no positive earnings and no EV / Sales): Sarepta Therapeutics, Inc., Acadia Healthcare Company, Inc., Neogen Corporation.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Sarepta Therapeutics, Inc.SRPTthis company$1.8B-2.5x1.5x-62.5%-3.2x
TransMedics Group, Inc.TMDX$2.5B13.0x5.2x40.2%16.8x
Acadia Healthcare Company, Inc.ACHC$2.3B-2.1x1.2x-56.6%-6.5x
Prestige Consumer Healthcare Inc.PBH$2.2B11.3x1.1x10.1%9.5x
LeMaitre Vascular, Inc.LMAT$2.1B37.0x5.4x14.7%25.3x
Select Medical Holdings CorporationSEM$2.0B14.0x1.2x8.6%9.2x
Neogen CorporationNEOG$2.0B-1.8x1.0x-52.7%-2.9x
ADMA Biologics, Inc.ADMA$1.8B12.6x3.9x30.8%9.3x
Phibro Animal Health CorporationPAHC$1.3B27.8x4.7x16.9%13.8x
Peer median—12.8x2.5x12.4%9.4x

Year-to-date ROI

SRPT since 1 January, against earlier years.

Historical volatility

SRPT's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Sarepta Therapeutics, Inc. operating margin by fiscal year
Sarepta Therapeutics, Inc. operating margin by fiscal year
DateOperating margin
FY2022-57.5%
FY2023-21.5%
FY202411.5%
FY2025-29.9%
LineFY2025
Cost of revenueCost Of Revenue$839.6M
Gross profitGross Profit$1.4B
Operating expensesOperating Expense$2.0B
Research and developmentResearch And Development$1.5B
Depreciation and amortisationDepreciation And Amortization In Income Statement$2.6M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$2.6M
Amortization$2.6M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$2.6M
Total expensesTotal Expenses$2.9B
Pretax incomePretax Income-$702.2M

Learn while you research

Academy chapters picked for Sarepta Therapeutics, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  3. 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  4. 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →